The Ukrainian Company has selected Stratesys GxP Suite, an industry solution for quality management process automation, developed by the spanish system integrator as an add-on to the Opentext enterpise information management platform
Darnitsa, leading pharmaceutical product manufacturer based in Ukraine, has selected the spanish multinational Stratesys, to execute the digital transformation process of pharmaceutical product life cycle management, including quality management. The project includes the implementation of the 4 modules that are currently included in GxP Suite, designed by Stratesys to automate the product development and quality management systems of Life Science and Pharmaceutical organizations.
This solution adoption is part of the global up to date program launched by the Company that pursues, amongst other goals, improve the quality control of their production systems: simplify their product registry procedures to help their entry in new markets; enable compliance with local and international regulations regarding general manufacturing procedures and consolidate the clinical trial related information within their Research and Development group.
Within the framework of this innovation strategy, Darnitsa has selected SAP Extended ECM by Opentext as the core solution for Enterprise Information Management. With this last generation platform, Opentext provides the technologies to cover all the information digitalization initiatives that an organization might have, so that content is brought in context of the corporate processes managed by SAP.
Andriy Romanenko, Darnitsa’s CIO, states that “this project is a key pillar of the companies growth plan, that in first instance, aims to be present in new markets in Europe and APAC”. Collaborating with Darnitsa is an example of the international competence and capabilities that the spanish technology system integrators have, which in Stratesys is reflected in over 1000 projects executed in over 60 countries worldwide.
The Managing Partner of the Life Science Industry, Luis Fernández-Sanguino Peña, highlights the “remarkable investment of the firm on developing industry specific solutions, in particular, for the life science and chemical industry that is, currently, undergoing a big transformation process due to the pressing regulatory changes and the challenges of globalization”.
This news has been published in